Assessment of effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular age-related macular degeneration

Purpose: To evaluate the effect of intravitreal ranibizumab injection on the ocular blood flow in patients with neovascular agerelated
macular degeneration (AMD).

Methods: 35 patients with wet AMD undergone intravitreal 0.5 mg ranibizumab injection. Color Doppler Imaging (CDI) and dopplerography
were used to measure hemodynamic parameters including the peak systolic velocity (Vsyst, cm / s), end-diastolic velocity (V diast, cm / s), and resistance index (RI) of blood flow in the central retinal artery (CRA), the short posterior ciliary arteries (PCA), and the ophthalmic artery (OA). All patients were examined before and after injection on day 1‑7 and 30 day during the 3‑month follow up period.

Results: Before intravitreal injection Vsyst was decreased in short PCA (p<0.05), RI in CRA and in short PCA significantly increased in comparison with normal index in same vessels. The peak systolic velocity in OA, in CRA and in short PCA was not significantly changed. After second injection resistance index in CRA and in short PCA was normalized.

Conclusion: There was not impairment of ocular blood flow in retinal and choroidal after monthly intravitreal injection of ranibizumab during the 3‑month follow up period.

1. Киселева Т. Н., Кравчук Е. А., Лагутина Ю. М. и др. Особенности глазного кровотока и состояния брахиоцефальных артерий у больных с неэкссудативной возрастной макулярной дегенерацией // Вестн. офтальмол. 2006. Т. 122, № 4. С. 12‑14.

2. Нероев В. В., Рябина М. В., Чиковани К. Р. и др. Современные представления и подходы к лечению возрастной макулярной дегенерации // Рос. офтальмол. журн. 2008. Т. 1, № 1. С. 6‑9.

3. Bakri S. J., Snyder M. R., Reid J. M. Pharmacokinetics of intravitreal bevacizumab (Avastin) // Ophthalmology. 2007. V.114. P. 855‑859.

4. Bakri S. J., Snyder M. R., Reid JM. Pharmacokinetics of intravitreal ranibizumab (Lucentis) // Ophthalmology. 2007. V. 114. P. 2179‑2185.

5. Bhisitkul R. B. Vascular endothelial growth factor biology: clinical implications for ocular treatments // Br J Ophthalmol. 2006. V. 90. P. 1542‑1547.

6. Bonnin P, Pournaras J. A., Lazrak Z. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin) in neovascular age-related macular degeneration // Acta Ophthalmol. 2010. V. 88. P.641‑648.

7. Chang T. S., Bressler N. M., Fine J. T., et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial // Arch Ophthalmol. 2007. V. 125. P.1460‑1469.

8. Ciulla T. A., Harris A., Chung H. S. Color Doppler imaging discloses reduced ocular blood flow velocities in nonexudative age-related macular degeneration //Am J Ophthalmol. 1999. V. 128. P. 75‑80.

9. Gaudreault J., Fei D., Rusit J., et al. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration // Invest Ophthalmol Vis Sci. 2005. V. 46. P. 726‑733.

10. Klein R., Klein B. E., Linton K. L. Prevalence of age related maculopathy. The Beaver Dam Eye Study // Ophthalmology. 1992. V. 99. P. 933‑943.

11. Kourlas H., Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review // Clin Ther. 2007. V. 29. P. 1850‑1861.

12. Krohne T. U., Eter N., Holz F. G. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans // Am J Ophthalmol. 2008. V. 146. P. 508‑512.

13. Kvanta A., Algvere P. V., Berglin L., Seregard S. Subfoveal fibrovascular membranes in age related macular degeneration express vascular endothelial growth factor // Invest Ophthalmol Vis Sci. 1996. V. 37. P. 1929‑1934.

14. Mete A., Saygili O., Mete A., et al. Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular agerelated macular degeneration // J Clin Ultrasound. 2010. V. 38. P. 66‑70.

15. Mete A., Saygili O., Mete A., et al. Does ranibizumab (Lucentis) change retrobulbar blood flow in patients with neovascular age-related macular degeneration?// Ophthalmic Res. 2012. V. 47. P. 141‑145.

16. Riva C. E. Sub-foveal choroidal blood flow by LDF: measurement and application to the physiology and pathology of the choroidal circulation // Bull Soc Belge Ophtalmol. 2006. V. 302. P. 185‑194.

17. Sakalar Y. B., Senturk S., Yildirim M., et al. Evaluation of retrobulbar blood flow by color Doppler ultrasonography after intravitreal ranibizumab injection in patients with neovascular age-related macular degeneration // J. Clin. Ultrasound.

18. V. 41. P.32‑37.

19. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration // Expert Opin Drug Saf. 2010. V. 9. P. 149‑165.

20. Uretmen O., Akkin C., Erakgun T., Killi R. Color Doppler imaging ofchoroidal circulation in patients with asymmetric age-related macular degeneration // Ophthalmologica. 2003. V. 217. P.137‑142.

21. Von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy // Acta Ophthalmol. 2010. V. 88. P. 263‑266.